C. Jillian Tsai, MD, PhD, on Using Stereotactic Body Radiotherapy to Reduce Oligoprogression in Advanced Lung Cancer

Posted: Tuesday, November 2, 2021

C. Jillian Tsai, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses results from the CURB study, which suggests that adding stereotactic body radiation therapy to the drug regimen for patients with oligoprogressive, metastatic lung cancer may improve progression-free survival.